Acceptability of the human papillomavirus vaccine and reasons for non-vaccination among parents of adolescent sons

Abstract Routine administration of the quadrivalent human papillomavirus (HPV) vaccine has been recommended for 11–12-year-old males since 2011, but coverage remains low. In a U.S. national sample of parents of 11–17-year-old males ( n = 779), 78.6% of parents reported their sons had not received th...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine Vol. 32; no. 31; pp. 3883 - 3885
Main Authors: Donahue, Kelly L, Stupiansky, Nathan W, Alexander, Andreia B, Zimet, Gregory D
Format: Journal Article
Language:English
Published: Kidlington Elsevier Ltd 30-06-2014
Elsevier
Elsevier Limited
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Routine administration of the quadrivalent human papillomavirus (HPV) vaccine has been recommended for 11–12-year-old males since 2011, but coverage remains low. In a U.S. national sample of parents of 11–17-year-old males ( n = 779), 78.6% of parents reported their sons had not received the HPV vaccine. The most common reason for non-vaccination (56.7%) was “My doctor or healthcare provider has not recommended it.” Parents citing only logistical reasons for non-vaccination (e.g., lack of recommendation, access, or education, n = 384) reported significantly higher vaccine acceptability than parents reporting a combination of attitudinal (e.g., concerns about vaccine safety or efficacy) and logistical barriers ( n = 92), while parents citing only attitudinal barriers ( n = 73) reported the lowest level of vaccine acceptability. In sum, many parents are willing but have not vaccinated sons due to logistical barriers, most commonly lack of healthcare provider recommendation. These findings have important implications for increasing HPV vaccination coverage among adolescent males.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2014.05.035